FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study
Creators: name: Roussel-Simonin, Cyril
name: Gougis, Paul
name: Lassoued, Donia
name: Vozy, Aurore
name: Veyri, Marianne
name: Morardet, Laetitia
name: Wassermann, Johanna
name: Tichoue, Hervé Foka
name: Jaffrelot, Loïc
name: Hassani, Lamia
name: Perrier, Alexandre
name: Bergeret, Sebastien
name: Taillade, Laurent
name: Spano, Jean-Philippe
name: Campedel, Luca
name: Abbar, Baptiste
Publisher: name: Taylor & Francis
Year: 2023
Subjects: subject: Physical Sciences not elsewhere classified
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Ecology
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Science Policy
subject: Hematology
subject: Plant Biology

description: Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer and is associated with poor prognosis. In platinum-refractory or -resistant SCLC patients, few treatment options are available. Topotecan is one of the standards of care for these patients, however, due to its high toxicity, several different approaches are employed. FOLFIRI (folinate, 5-fluorouracil and irinotecan) is a chemotherapy regimen used in digestive neuroendocrine carcinoma, which shares pathological similarities with SCLC. In this retrospective study, we evaluated the efficacy and safety of FOLFIRI in patients with platinum-resistant/refractory SCLC. Medical records from all consecutive SCLC patients treated with FOLFIRI in a French University Hospital from 2013 to 2021 were analyzed retrospectively. The primary endpoint was the objective response rate according to RECIST v1.1 or EORTC criteria (ORR); secondary endpoints included duration of response, disease control rate, progression-free survival (PFS), overall survival (OS) and safety profile. Thirty-four patients with metastatic platinum-resistant (<i>n</i> = 14) or -refractory (<i>n</i> = 20) SCLC were included. Twenty-eight were evaluable for response, with a partial response observed in 5 patients for an overall ORR in the evaluable population of 17.9% (5/28) and 14.7% (5/34) in the overall population. The disease control rate was 50% (14/28) in the evaluable population. The median PFS and OS were 2.8 months (95%CI, 2.0–5.2 months) and 5.3 months (95%CI, 3.5–8.9 months), respectively. All patients were included in the safety analysis. Grade 3 or 4 adverse events occurred in 13 (38.2%) patients. The most common grade 3 or 4 adverse events were asthenia, neutropenia, thrombopenia and diarrhea. There was no adverse event leading to discontinuation or death. FOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response and had an acceptable safety profile. However, caution is needed in interpreting this result. FOLFIRI could represent a potential new treatment for platinum-resistant/refractory SCLC patients. Further prospective studies are needed to assess the benefits of this chemotherapy regimen.HIGHLIGHTSFOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response.FOLFIRI was well-tolerated in platinum resistant/refractory SLCL patients.FOLFIRI could represent a potential new treatment for SCLC, prospective studies are needed. FOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response. FOLFIRI was well-tolerated in platinum resistant/refractory SLCL patients. FOLFIRI could represent a potential new treatment for SCLC, prospective studies are needed.